Previous 10 | Next 10 |
— Company Advances Clinical and Pre-Clinical Pipeline Designed to Bring Therapies to Patients With Unmet Medical Needs — Exicure, Inc. ® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA&...
It has been 13 months since we last looked at small early stage developmental firm called Exicure. The company's development efforts originate from the proprietary Spherical Nucleic Acid, or SNA, technology, and it has a couple of compounds in development. A full analysis follows ...
Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, is pleased to share that researchers at Northwestern University have utilized Exicure’s licensed first generation gold-nanoparticle SN...
Exicure (XCUR): FY GAAP EPS of -$0.28 misses by $0.02.Revenue of $16.6M (+1176.9% Y/Y) misses by $2.36M.Shares +5.15%.Press Release For further details see: Exicure EPS misses by $0.02, misses on revenue
– Granted two Fast Track designations for cavrotolimod (AST-008) from the U.S. Food and Drug Administration (FDA) in January 2021 and an Orphan Drug Designation in March 2021 – Commenced IND-enabling studies on XCUR-FXN Friedreich’s ataxia in late 2020 ...
Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced the appointments of Elizabeth (Betsy) Garofalo, M.D. and Mr. Andrew Sassine to its Board of Directors. “We are ple...
The FDA has granted an Orphan Drug Designation to Exicure's (XCUR) cavrotolimod (AST-008), for the treatment of patients with Merkel cell carcinoma ((MCC)).Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved. FDA ha...
Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its clinical product candidate, cavr...
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced that CEO David Giljohann will present at the 2021 H.C. Wainwright Global Life Sciences Conference, March 9-10, 2021. The ...
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced participation in a series of 1x1 meetings with institutional investors at the 10th Annual SV Leerink Global Healthcare Confer...
News, Short Squeeze, Breakout and More Instantly...
Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activiti...
Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on April 17, 2024 notifying the Company that, as a result of the Company’s failure to timely f...
GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...